REGENXBIO

$39.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.93 (-2.32%) Today

$0.00 (0.00%) As of 9:20 PM UTC after-hours

Why Robinhood?

You can buy or sell REGENXBIO and other stocks, options, and ETFs commission-free!

About RGNX

REGENXBIO Inc. Common Stock, also called REGENXBIO, is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. The listed name for RGNX is REGENXBIO Inc. Common Stock.

CEO

Kenneth T. Mills

Employees

257

Headquarters

Rockville, Maryland

Founded

2008

Market Cap

1.62B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

432.72K

High Today

$40.61

Low Today

$38.35

Open Price

$39.75

Volume

418.57K

52 Week High

$50.26

52 Week Low

$20.03

RGNX News

BenzingaMar 1

Recap: Regenxbio Q4 Earnings

Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.22% over th

Analyst Ratings

78%

of 9 ratings

Buy

78%

Hold

22%

Sell

RGNX Earnings

-$1.24

-$0.75

-$0.26

$0.23

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.43 per share

Actual

-$1.24 per share

Replay Earnings Call